Literature DB >> 12023830

The ProteinChip Biomarker System from Ciphergen Biosystems: a novel proteomics platform for rapid biomarker discovery and validation.

K Chapman1.   

Abstract

Protein biochips are emerging in two distinct formats. The first involves high-density immobilized arrays of recognition molecules (e.g. antibodies), where target binding is monitored indirectly (e.g. via fluorescence). This technology is in its infancy, being limited by the availability of suitable binding molecules that can cope effectively with protein diversity. The second format involves the capture of proteins by biochemical or intermolecular interaction, coupled with direct detection by MS. This technology is available as the ProteinChip Biomarker System. ProteinChip technology uses surface-enhanced laser desorption/ionization processes to analyse proteins directly from biological samples. Chromatographic surfaces are placed on to ProteinChip Arrays and used to capture subclasses of proteins, dependent on their physical properties. Time-of-flight MS then assigns native molecular masses to the captured proteins. Reproducible protein profiles can be generated from crude biological fluids (e.g. cell lysates, urine or serum). The technology is being applied to a wide range of disciplines, from plant sciences to cancer research, and will be reviewed here.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023830     DOI: 10.1042/

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  8 in total

Review 1.  Application of proteomics to the study of polycystic ovary syndrome.

Authors:  M Insenser; H F Escobar-Morreale
Journal:  J Endocrinol Invest       Date:  2011-11-21       Impact factor: 4.256

2.  Discrimination of normal and esophageal cancer plasma proteomes by MALDI-TOF mass spectrometry.

Authors:  John Schwacke; Timothy P Millar; Charles E Hammond; Arindam Saha; Brenda J Hoffman; Joseph Romagnuolo; Elizabeth G Hill; Adam J Smolka
Journal:  Dig Dis Sci       Date:  2015-01-11       Impact factor: 3.199

3.  Discovering differential protein expression caused by CagA-induced ERK pathway activation in AGS cells using the SELDI-ProteinChip platform.

Authors:  Zhen Ge; Yong-Liang Zhu; Xian Zhong; Jie-Kai Yu; Shu Zheng
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

4.  Detection of cancer-specific markers amid massive mass spectral data.

Authors:  Wei Zhu; Xuena Wang; Yeming Ma; Manlong Rao; James Glimm; John S Kovach
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

5.  Biomarkers for detection and surveillance of bladder cancer.

Authors:  Lorne I Budman; Wassim Kassouf; Jordan R Steinberg
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

Review 6.  Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry.

Authors:  Jose L Luque-Garcia; Thomas A Neubert
Journal:  J Chromatogr A       Date:  2006-12-12       Impact factor: 4.759

Review 7.  Advances in Proteomic Technologies and Its Contribution to the Field of Cancer.

Authors:  Mehdi Mesri
Journal:  Adv Med       Date:  2014-09-07

Review 8.  Cytokines as biomarkers in rheumatoid arthritis.

Authors:  Agata Burska; Marjorie Boissinot; Frederique Ponchel
Journal:  Mediators Inflamm       Date:  2014-03-09       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.